Hemagglutination inhibiting antibody persistence 1 year after influenza vaccination in Korean children and adolescents

This study aimed to assess the 1-y immunogenicity of influenza vaccines and the association between immunogenicity at 1 m and further influenza infections in children aged 6 m to 18 y. Serum hemagglutination inhibition (HI) antibody titers and GMTs were determined for the recommended influenza strai...

Full description

Saved in:
Bibliographic Details
Main Authors: Eun Kyeong Kang (Author), Byung Wook Eun (Author), Nam Hee Kim (Author), Yun Kyung Kim (Author), Jung Sub Lim (Author), Dong Ho Kim (Author)
Format: Book
Published: Taylor & Francis Group, 2017-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_02ce38d36cf94a0586d1755f0bc03e4f
042 |a dc 
100 1 0 |a Eun Kyeong Kang  |e author 
700 1 0 |a Byung Wook Eun  |e author 
700 1 0 |a Nam Hee Kim  |e author 
700 1 0 |a Yun Kyung Kim  |e author 
700 1 0 |a Jung Sub Lim  |e author 
700 1 0 |a Dong Ho Kim  |e author 
245 0 0 |a Hemagglutination inhibiting antibody persistence 1 year after influenza vaccination in Korean children and adolescents 
260 |b Taylor & Francis Group,   |c 2017-04-01T00:00:00Z. 
500 |a 2164-5515 
500 |a 2164-554X 
500 |a 10.1080/21645515.2016.1259044 
520 |a This study aimed to assess the 1-y immunogenicity of influenza vaccines and the association between immunogenicity at 1 m and further influenza infections in children aged 6 m to 18 y. Serum hemagglutination inhibition (HI) antibody titers and GMTs were determined for the recommended influenza strains 0, 1, 6, and 12 m post-vaccination. The serological evidence of influenza infections were defined as the increase of HI titer (HI ≥1:40 and 4-fold rise). The seroprotection rates for strains A(H1N1), A(H3N2), and B were 91.2%, 87.6%, and 87.6%, respectively, at 1 month (n = 174). These rates were 76.5%, 64.7%, and 54.6%, respectively, at 12 m. The seroprotection rates and GMTs for influenza A(H1N1) and A(H3N2) were higher at 12 m than at 0 m (p < 0.05) but not for B. There were 39 subjects (42 cases) of serological influenza infections. Subjects with seroprotection at 1 m post-vaccination had showed fewer serologic A(H1N1) (10.1 vs 54.5%) and A(H3N2) (7.2 vs 38.1%) infections than the ones with HI titer <1:40 during follow-up (P < 0.01). In conclusion, influenza vaccines used during the 2008-09 season induced adequate 1-y immunogenicity for A(H1N1) and A(H3N2). The immunogenicity at one month after vaccination influenced further serological influenza infections. 
546 |a EN 
690 |a 1-year immunogenicity 
690 |a children 
690 |a hemagglutination inhibition 
690 |a influenza vaccine 
690 |a seroprotection rate 
690 |a Immunologic diseases. Allergy 
690 |a RC581-607 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Human Vaccines & Immunotherapeutics, Vol 13, Iss 4, Pp 895-902 (2017) 
787 0 |n http://dx.doi.org/10.1080/21645515.2016.1259044 
787 0 |n https://doaj.org/toc/2164-5515 
787 0 |n https://doaj.org/toc/2164-554X 
856 4 1 |u https://doaj.org/article/02ce38d36cf94a0586d1755f0bc03e4f  |z Connect to this object online.